ID   HEL-N1
AC   CVCL_A5ZL
DR   cancercelllines; CVCL_A5ZL
DR   Wikidata; Q107115311
RX   PubMed=7538619;
CC   Population: Caucasian.
CC   Characteristics: Subline that does not expresses KIT (PubMed=7538619).
CC   Doubling time: 19.0 +- 0.8 hours (Note=In serum-containing medium), 24.0 +- 1.1 hours (Note=In serum-free medium) (PubMed=7538619).
CC   Sequence variation: Mutation; HGNC; HGNC:6192; JAK2; Simple; p.Val617Phe (c.1849G>T); ClinVar=VCV000014662; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Met133Lys (c.398T>A); ClinVar=VCV002430159; Zygosity=Homozygous (from parent cell line).
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
DI   NCIt; C7152; Erythroleukemia
DI   ORDO; Orphanet_318; Acute erythroid leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0001 ! HEL
SX   Male
AG   30Y
CA   Cancer cell line
DT   Created: 20-05-21; Last updated: 19-12-24; Version: 6
//
RX   PubMed=7538619; DOI=10.1016/0145-2126(94)00160-c;
RA   Kubota A., Okamura S., Shimoda K., Ikematsu W., Otsuka T., Niho Y.;
RT   "Analysis of c-kit expression of human erythroleukemia cell line, HEL:
RT   clonal variation and relationship with erythroid and megakaryocytic
RT   phenotype.";
RL   Leuk. Res. 19:283-290(1995).
//